User:Adam Davis/Sandbox 1: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Adam Davis (talk | contribs) No edit summary |
Adam Davis (talk | contribs) No edit summary |
||
| Line 21: | Line 21: | ||
== Disease == | == Disease == | ||
PPARδ agonists are being investigated as treatments for a number of metabolic disorders, but have not yet been deployed clinically. Though there are some health benefits associates with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain for PPARα, and carcinogenicity for PPARγ<ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that does not also bind to the other PPARs. | PPARδ agonists are being investigated as treatments for a number of metabolic disorder and cardiovascular disorders, but have not yet been deployed clinically. Current literature suggests that PPARδ agonists could enhance fatty acid oxidation in skeletal muscle, reduce serum triglycerides, increase serum high density lipoprotein (HDL) cholesterol and stimulate aspects of reverse cholesterol transport, improve glucose homeostasis, and trigger thermogenesis and weight loss. Though there are some health benefits associates with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain for PPARα, and carcinogenicity for PPARγ<ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that does not also bind to the other PPARs. | ||
== Relevance == | == Relevance == | ||
